1 not yet recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow David Simon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy - ANCA-IgG-positive ANCA Associated Vasculitis | Phase 1 / Phase 2 | Not yet recruiting | David Simon | 8 | 2025-01-01 | 2024-09-19 |
HIV Seropositivity (1) · Vasculitis (1)
PMID 12631091, PMID 18528326, PMID 2161532, PMID 21859691, PMID 32291416, PMID 32855422, PMID 34347960, PMID 34501224, PMID 36109639, PMID 36927642, PMID 37748491, PMID 38182404, PMID 38381673